These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 12124334

  • 1. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
    Ojo-Amaize EA, Nchekwube EJ, Cottam HB, Bai R, Verdier-Pinard P, Kakkanaiah VN, Varner JA, Leoni L, Okogun JI, Adesomoju AA, Oyemade OA, Hamel E.
    Cancer Res; 2002 Jul 15; 62(14):4007-14. PubMed ID: 12124334
    [Abstract] [Full Text] [Related]

  • 2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 3. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, Marmé D, Unger C.
    Anticancer Res; 2004 Sep 15; 24(3a):1759-63. PubMed ID: 15274352
    [Abstract] [Full Text] [Related]

  • 4. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 5. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth.
    Liu N, Lapcevich RK, Underhill CB, Han Z, Gao F, Swartz G, Plum SM, Zhang L, Green SJ.
    Cancer Res; 2001 Feb 01; 61(3):1022-8. PubMed ID: 11221828
    [Abstract] [Full Text] [Related]

  • 6. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
    Petitclerc E, Deschesnes RG, Côté MF, Marquis C, Janvier R, Lacroix J, Miot-Noirault E, Legault J, Mounetou E, Madelmont JC, C -Gaudreault R.
    Cancer Res; 2004 Jul 01; 64(13):4654-63. PubMed ID: 15231678
    [Abstract] [Full Text] [Related]

  • 7. Goniodomin A, an antifungal polyether macrolide, exhibits antiangiogenic activities via inhibition of actin reorganization in endothelial cells.
    Abe M, Inoue D, Matsunaga K, Ohizumi Y, Ueda H, Asano T, Murakami M, Sato Y.
    J Cell Physiol; 2002 Jan 01; 190(1):109-16. PubMed ID: 11807817
    [Abstract] [Full Text] [Related]

  • 8. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities.
    Sheu JR, Fu CC, Tsai ML, Chung WJ.
    Anticancer Res; 1998 Jan 01; 18(6A):4435-41. PubMed ID: 9891506
    [Abstract] [Full Text] [Related]

  • 9. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
    Hagedorn M, Zilberberg L, Wilting J, Canron X, Carrabba G, Giussani C, Pluderi M, Bello L, Bikfalvi A.
    Cancer Res; 2002 Dec 01; 62(23):6884-90. PubMed ID: 12460903
    [Abstract] [Full Text] [Related]

  • 10. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.
    He GA, Luo JX, Zhang TY, Hu ZS, Wang FY.
    Biochem Biophys Res Commun; 2004 May 28; 318(2):354-60. PubMed ID: 15120609
    [Abstract] [Full Text] [Related]

  • 11. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain.
    Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, Zhang JC, Rabbani SA, McCrae KR, Mazar AP, Morgan WT, Doñate F.
    Cancer Res; 2002 Sep 15; 62(18):5344-50. PubMed ID: 12235005
    [Abstract] [Full Text] [Related]

  • 12. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
    Burres NS, Clement JJ.
    Cancer Res; 1989 Jun 01; 49(11):2935-40. PubMed ID: 2720652
    [Abstract] [Full Text] [Related]

  • 13. Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.
    Mousa SA, Mohamed S, Wexler EJ, Kerr JS.
    Anticancer Res; 2005 Jun 01; 25(1A):197-206. PubMed ID: 15816539
    [Abstract] [Full Text] [Related]

  • 14. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
    Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J.
    Cancer Res; 2001 Nov 01; 61(21):7830-9. PubMed ID: 11691800
    [Abstract] [Full Text] [Related]

  • 15. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S, Sellers LA, Cindrova T, Skepper J, Gherardi E, Sasisekharan R, Fan TP.
    Cancer Res; 2003 Dec 01; 63(23):8351-9. PubMed ID: 14678996
    [Abstract] [Full Text] [Related]

  • 16. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
    Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM.
    Cancer Res; 2003 May 01; 63(9):2079-87. PubMed ID: 12727823
    [Abstract] [Full Text] [Related]

  • 17. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor.
    Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K, Mumm JB, Stewart AL, Boquoi A, Dumoutier L, Grimm EA, Renauld JC, Kotenko S, Chada S.
    Cancer Res; 2003 Aug 15; 63(16):5105-13. PubMed ID: 12941841
    [Abstract] [Full Text] [Related]

  • 18. Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth.
    He GA, Luo JX, Zhang TY, Wang FY, Li RF.
    Biochem Biophys Res Commun; 2003 Dec 19; 312(3):801-5. PubMed ID: 14680836
    [Abstract] [Full Text] [Related]

  • 19. Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor.
    Park MJ, Park IC, Bae IJ, Seo KM, Lee SH, Hong SI, Eun CK, Zhang W, Rhee CH.
    Int J Oncol; 2003 Jun 19; 22(6):1271-6. PubMed ID: 12738993
    [Abstract] [Full Text] [Related]

  • 20. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.
    Cancer Res; 2004 May 15; 64(10):3586-92. PubMed ID: 15150116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.